AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04585477 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Durvalumab (Imfinzi) alone or in combination with platinum-based chemotherapy
Description: Participants in the intervention arm (Cohort 1 MRD+) will receive a fixed dose of Durvalumab (1500 mg IV every 4 weeks for up to 12 months), either as monotherapy or in combination with a platinum-based chemotherapy regimen (investigator's choice). Platinum-based chemotherapy options include carboplatin, cisplatin, pemetrexed, paclitaxel, or nab-paclitaxel, administered per standard of care for up to 4 cycles.
Study NCT05739279 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Chair Stand Test
Description: For the 5-repeat stand-up test, patients will be asked to get up from a chair without an armrest and sit (at the start) five times as fast as possible with their arms crossed over their chest.
Study NCT06430866 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABP 234
Description: Administered by intravenous (IV) injection.
Study NCT06430866 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: Administered by IV injection.
Study NCT06190223 — intervention group
Intervention type: PROCEDURE
Intervention: Anterior cruciate ligament (ACL) reconstruction with a periost-patellar-tendon-bone (PPTB) autograft and a tibial press-fit technique
Description: A longitudinal incision will be performed starting from the central part of the patella. A ruler will be used to mark a tendon thickness of 10mm from the middle of the patellar tendon. Superiorly, the patellar periosteum will be marked with a length of 30-40mm and a width of 10mm. Inferiorly, the tibial tubercle will be marked in a trapezoidal shape with a length of approximately 35mm, a superior narrow base of 10mm and an inferior wider base of 12mm. After extraction, the superior part of the graft will be prepared with reinforced sutures in a whipstitch pattern, while the bone block will be shaped according to the planned tunnel width. After adequate preparation, the femoral end of the graft will be shuttled in with an adjusted fixation device, while the tibial end will be hammered in with a small mallet, in a press-fit fashion, stopping short of the joint surface, but tensioned appropriately. The femoral adjustable device will then be tensioned to ensure proper graft sitting.
Study NCT04910724 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Energy Deficit
Description: A combination of individualized exercise performed on a cycle ergometer and individualized dietary prescriptions will be used to achieve energy balance or the assigned energy deficits throughout the controlled feeding and testing periods
Study NCT05739279 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: 6 Meter Gait Speed
Description: For walking speed measurements, patients will be asked to stand with both feet touching the starting line and walk at their normal speed on a 6-meter track after the command. The time between the start and end will be measured with a stopwatch and converted to meters/second. Three consecutive measurements will be made for both and average values will be taken for the analyses.
Study NCT05062889 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil continuous infusion FOLFOXIRI schedule
Description: 3200 mg/sqm 48 h-continuous infusion, starting on day 1. To be repeated every two weeks for a maximum of 12 cycles.
Study NCT05960578 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apalutamide
Description: Given PO
Study NCT05960578 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo tumor biopsy
Study NCT05960578 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples
Study NCT05960578 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan
Study NCT05960578 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Golimumab
Description: Given SC
Study NCT05960578 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT05062889 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-Fluorouracil bolus FOLFOX schedule
Description: 400 mg/sqm iv bolus, day 1. To be repeated every two weeks for a maximum of 12 cycles.
Study NCT05062889 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil bolus FOLFOX schedule
Description: 400 mg/sqm iv bolus, day 1. To be repeated every two weeks for a maximum of 12 cycles.
Study NCT05062889 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-Fluorouracil continuous infusion FOLFOX schedule
Description: 2400 mg/sqm 48 h-continuous infusion, starting on day 1. To be repeated every two weeks for a maximum of 12 cycles.
Study NCT05062889 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil continuous infusion FOLFOX schedule
Description: 2400 mg/sqm 48 h-continuous infusion, starting on day 1. To be repeated every two weeks for a maximum of 12 cycles.
Study NCT05062889 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin FOLFOX and FOLFOXIRI schedule
Description: 85 mg/sqm iv over 2 hours, day 1. To be repeated every two weeks for a maximum of 12 cycles.
Study NCT05960578 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PSMA PET Scan
Description: Undergo PSMA PET
Study NCT06304181 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol and Mannitol Injection
Description: Paracetamol and Mannitol Injection 500mg
Study NCT06304181 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Parecoxib
Description: 40mg of parecoxib
Study NCT05062889 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin FOLFOX and FOLFOXIRI schedule
Description: 85 mg/sqm iv over 2 hours, day 1. To be repeated every two weeks for a maximum of 12 cycles.
Study NCT05343494 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Intervention
Description: The intervention has been modified from a subset of sessions from the National DPP Prevent T2 Curriculum (an adapted DPP for community settings that improves cardiometabolic outcomes and is implemented nationwide).~The intervention will consist of 8 weekly sessions. The first session will be one-on-one and subsequent sessions will be in small groups. Sessions 1, 2, and 6 will be in-person and other sessions will be held by Zoom.
Study NCT05062889 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin CAPOX schedule
Description: 130 mg/sqm iv over 2 hours, day 1. To be repeated every three weeks for a maximum of 8 cycles.
Study NCT05062889 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin CAPOX schedule
Description: 130 mg/sqm iv over 2 hours, day 1. To be repeated every three weeks for a maximum of 8 cycles.
Study NCT05062889 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: L-Leucovorin
Description: 200 mg/sqm iv over 2 hours, day 1. To be repeated every two weeks for a maximum of 12 cycles.
Study NCT05358262 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Airvo
Description: Fisher \& Paykel's AIRVO 2 is a humidifier with integrated flow generator that delivers high flow warmed and humidified respiratory gases to spontaneously breathing patients through a variety of interfaces including nasal cannula. Flow can be delivered from 2 to 60 LPM
Study NCT05358262 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: The standard of care for mucositis at the Cross Cancer institute involves supportive therapies including oral hydration (water or wet sponges) or medicated mouthwashes.
Study NCT05312515 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Warm Application to Feet
Description: Warm Application to Feet after Cesarean Section
Study NCT05698355 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telerehabilitation Treatment
Description: Telerehabilitation includes self-massages for pelvic floor muscle, sex education, breathing, myofascial releasing with wand, and pelvic floor relaxing exercises.
Study NCT05682937 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HFOV-sigh
Description: HFOV-sigh setting both SLE6000 and Drager Babylog VN500: setting (Hz, MAP, delta pressure) same as HFOV, set sigh RR 3 breath/min, Sigh Ti = 1 sec, Sigh PIP = (MAP+5, maximum 30) cm H2O, Slope sigh 0.5.
Study NCT05062889 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-Leucovorin
Description: 200 mg/sqm iv over 2 hours, day 1. To be repeated every two weeks for a maximum of 12 cycles.
Study NCT06379217 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [68Ga]Ga-PSMA-11
Description: \[68Ga\]Ga-PSMA-11 will be administered as a single intravenous dose of approximately 150 MBq (4 mCi) to be administered during baseline imaging and approximately 7 weeks after last RLT dose. Administered dose should not be lower than 111 MBq (3 mCi) or higher than 259 MBq (7 mCi)
Study NCT06379217 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [68Ga]GA-DOTA-TATE
Description: \[68Ga\]Ga-DOTA-TATE will be administered as a single intravenous dose to be administered during baseline imaging and approximately 7 weeks after last RLT dose, within a range of 100-200MBq (2.7-5.4 mCi)
Study NCT05062889 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Capecitabine 1000 mg/sqm/bid per os from day 1 to day 14. To be repeated every 3 weeks until 8 cycles. Available as 500 and 150 mg tablets.
Study NCT06379217 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [68Ga]Ga-NeoB
Description: \[68Ga\]Ga-NeoB will be administered as a single intravenous dose to be administered during baseline imaging and approximately 7 weeks after last RLT dose.within a range of 150-250 MBq (4.1-6.8 mCi).
Study NCT06379217 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [177Lu]Lu-PSMA-617
Description: \[177Lu\]Lu-PSMA-617 will be administered as an intravenous infusion at a dose of 7.4 GBq (200mCi) (+/- 10%), every 6 weeks for 6 cycles.
Study NCT06379217 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [177Lu]Lu-DOTA-TATE
Description: \[177Lu\]Lu-DOTA-TATE will be administered as an intravenous infusion at a dose of 7.4 GBq (200mCi) (+/- 10%) every 6 weeks for 6 cycles.
Study NCT06379217 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [177Lu]Lu-NeoB
Description: \[177Lu\]Lu-NeoB will be administered as an intravenous infusion at a dose of 9.25 GBq (250mCi) every 6 weeks for 6 cycles
Study NCT06379217 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-Lysine HCl-L-Arginine HCl, 2.5 %,
Description: sterile solution for infusion Lysine HCl-Arginine HCl, 2.5 % (1L)
Study NCT06379217 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gonadotropin-releasing hormone (GnRH) analogues
Description: Anatomical Therapeutic Chemical \[ATC\] code L02AE
Study NCT06379217 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GnRH antagonists
Description: abarelix, degarelix, or relugolix
Study NCT06379217 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antiemetics & antinauseants
Description: ATC code A04A
Study NCT06379217 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metoclopramide
Description: ATC code A03FA01
Study NCT05062889 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: 165 mg/sqm iv over 60 minutes, day 1. To be repeated every two weeks for a maximum of 12 cycles.
Study NCT05062889 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trifluridine/Tipiracil
Description: 35 mg/m2/bid per os days 1-5 and 8-12. To be repeated every 4 weeks until 6 cycles. Available as 20 and 15 mg tablets.
Study NCT05062889 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: 4 mg/kg iv over 30 minutes, day 1 (loading dose: 6 mg/kg iv over 90 minutes). To be repeated every two weeks for a maximum of 12 cycles.
Study NCT05062889 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tucatinib
Description: 300 mg (two 150 mg tablets)/bid orally twice daily (approximately 8 to 12 hours between doses with or without a meal) for a maximum of 12 biweekly cycles.
Study NCT05949710 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: aerobic exercise(AE)
Description: The participants will receive AE three times per week.
Study NCT06398275 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam 20 MG Injection [Byfavo]
Description: Remimazolam 0.1 mg/kg intravenous injection
Study NCT06398275 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NaCl 0.9%
Description: NaCl 0.9% 0.04 mL/kg
Study NCT06483191 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy
Description: A half-day pre-operative virtual ACT group workshop, booster post-operative ACT text messages once a week for 6 weeks and a telephone follow-up with a physiotherapist at 6-8 weeks (all in addition to standard care).
Study NCT05410730 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1501
Description: SHR-1501 single agent dose escalation, and in combination of BCG or SHR-1316.
Study NCT05781152 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Anti-TNF therapy
Description: Use of anti-TNF therapy for children and adolescents with newly diagnosed Crohn's disease guided by a clinical decision support tool
Study NCT06381674 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vestibular therapy for mTBI augmented with audio and visual real-time biofeedback
Description: During physical therapy sessions participants will wear sensors on their head, chest, waist, and feet for real-time instrumented audio and visual biofeedback on quality of therapeutic exercise.
Study NCT06381674 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Vestibular therapy for mTBI
Description: During physical therapy sessions participants will go through vestibular therapeutic exercise WITHOUT audio and visual real-time biofeedback.
Study NCT06800131 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hepatitis B Vaccine administered trans-dermally via Microneedle Array Patch (MAP)
Description: A total of 40 subjects will be enrolled, 30 subjects administered trans-dermally via Microneedle Array Patch (MAP).
Study NCT05956314 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KM-001 cream 1% 12 weeks treatment.
Description: KM-001 1% will be supplied in glass jars (30 ml) and will be provided to patients with spatulas and polyethylene gloves on all the clinical visits. The patient will use IMP twice a day for 84 days. IMP will be applied on the plantar surfaces.
Study NCT05956314 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Physical Examination
Description: A complete physical examination will be performed as follows at screening and baseline, abbreviated after that (i.e., on Days 7, 28, 42, 63, 84, 112, 140, and at ET visit - where applicable, per cohort):~* The complete physical examination will cover a careful assessment of all body systems, including the head, eyes, ears, nose, and throat and the respiratory, cardiovascular, gastrointestinal (GI), musculoskeletal, neurological, dermatological, hematologic/lymphatic, and endocrine systems. Particular attention will be placed on the areas affected by the disease.~* Symptom-directed physical examinations will be performed at all other trial visits.~* Height and weight measurement will be performed at screening only. An abbreviated examination including a comprehensive skin examination.
Study NCT05956314 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Vital Signs
Description: Vital sign measurements (oral body temperature, pulse, and resting systolic and diastolic blood pressure) will be measured at screening, on Days 1, 7, 28, 42, 63, 84, 112, 140, and at ET visit - where applicable, per cohort. Vital signs will be measured in supine position after at least 5 minutes of rest.
Study NCT05956314 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Serum chemistry
Description: Approx. 5 mL whole blood will be collected after an ≥8 h fast for serum biochemistry assessments during screening, and on Days 1 (baseline), 7, 84 112, 140 or at an ET visit - where applicable, per cohort. Serum chemistry will include assessments of total and direct bilirubin, ALT, AST, gamma-glutamyl transferase (GGT), alkaline phosphatase, glucose (fasting), sodium, potassium, blood urea nitrogen (BUN/Urea), creatinine, chloride, calcium, uric acid, albumin, and total protein.
Study NCT05956314 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Hematology
Description: Approx. 5 mL whole blood will be collected for complete blood count (CBC) during screening, and on Days 1 (baseline), 7, 84, 112, 140 or at an ET visit - where applicable, per cohort. The CBC assessments will include red blood cells (RBC), haemoglobin, haematocrit, reticulocyte count, platelet count, mean corpuscular haemoglobin (MCH), mean platelet volume (MCV), white blood cells (WBC), neutrophils (absolute \[abs.\]), lymphocytes (abs.), monocytes (abs.), eosinophils (abs.), and basophils (abs.).
Study NCT05956314 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Serology
Description: Approx. 5 mL whole blood will be collected for serology assessments during screening. Serology will include HbsAg, HbcAb, hepatitis C antibody, and HIV antibody.
Study NCT05956314 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Urinalysis
Description: General urinalysis will be performed, by dipstick, during screening, and on Days 1 (baseline), 7, and 84, 112, and 140, or at an ET visit - where applicable, per cohort. At least 7 to 10 mL of urine will be collected. Urinalysis will include pH, specific gravity, blood, nitrites, glucose, ketones, protein, bilirubin, urobilinogen, and leukocytes. A microscopic examination of the urine will be performed only if clinically indicated.
Study NCT05956314 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: ECG test
Description: A 12-lead, resting, ECG will be taken for each patient at screening, on Days 1 (baseline), 84, 112, and at day 140 (for Cohort 2), or at an ET visit - Where applicable. The measurement will be taken after the patient has been supine for at least 5 min. At minimum, the following ECG parameters will be recorded: heart rate (HR), PR, QT, and QTc interval and QRS complex. The report will be printed out and signed by the investigator, who will record in the eCRF whether it is normal, abnormal but not clinically significant, or abnormal AND clinically significant. In the latter case the eligibility of the patients will be reviewed.
Study NCT04904276 — intervention group
Intervention type: DRUG
Intervention: Fostamatinib
Description: Fostamatinib disodium
Study NCT06800131 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Active comparator vaccine via intramuscular injection
Description: 10 subjects administered with active comparator vaccine via intramuscular injection.
Study NCT06027814 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Navigation and mHealth (PN+mHealth)
Description: Intervention consists of patient navigation with the mHealth adherence application facilitating telehealth visits, two-way chats, video-DOT, and delivery of financial incentives via smartphone.
Study NCT05425446 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DONQ52
Description: Subcutaneous (SC) injection
Study NCT05174520 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine Physical Therapy
Description: Routine physical therapy will be provided to group A for 25 minutes thrice a week for 4 weeks.
Study NCT05174520 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Muscle Energy Technique
Description: Muscle Energy technique along with Routine physical therapy will be provided to group B for40 minutes thrice a week for 4 weeks.
Study NCT05739370 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Problem-Solving Therapy for Older Adults
Description: Problem-Solving Therapy for Older Adults (Ger-iPST) is an 8-week online psychotherapy program with online therapist support delivered through the Online Psycho Therapy Tool (OPTT). Ger-iPST has several evidence-based elements tailored to the specific needs of older adults, including relevant content (e.g. aging-related examples); process adaptations (e.g. more repetition); and digital usability modifications (e.g. high-contrast text).~Ger-iPST contains therapy modules assigned weekly and accessible at any time during the week. Modules begin with a brief, guided mindfulness relaxation exercise, followed by approximately 20 slides taking, on an average 1 hour to complete. Each module highlights a different step of Psychotherapy (PST) and includes an overview of a new skill, interactive activities and examples. A homework exercise designed to guide participants in applying a new PST skill exercise is submitted through the platform, and a clinician will provide personalized feedback.
Study NCT04516057 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nabilone
Description: After the screening period, participants randomized to the nabilone arm will receive nabilone for 8 weeks. Participants will then be followed for 8 weeks following completion of the study treatment.
Study NCT04516057 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: After the screening period, participants randomized to the placebo arm will receive placebo capsules for 8 weeks. Participants will then be followed for 8 weeks following completion of the study treatment.
Study NCT05074810 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: avutometinib and sotorasib
Description: The RP2D of avutometinib + sotorasib determined in Part A will be used in Part B dose expansion